Healx, a Cambridge, UK-based developer of treatments for rare diseases, secured $10m in Series A funding.
The round was led by Balderton Capital with participation from Jonathan Milner and Amadeus Capital Partners. Balderton’s Suranga Chandratillake will be joining the Board alongside Shaun Grady (Global Vice-President Business Development Operations, AstraZeneca), Dr Hermann Hauser (Co-Founder of Amadeus Capital Partners), Dr Jonathan Milner (Founder and ex-CEO of Abcam, LON:ABC, and Founder of the Milner Institute for Therapeutics).
The company intends to use the funds to more than double its diverse and multi-disciplinary team of software engineers, data scientists, pharmacologists and drug development experts from the Cambridge ecosystem and to expand its artificial intelligence and machine learning technologies.
Founded in 2014 by Dr Tim Guilliams, a Bio-Chemical Engineer and founder of the Cambridge Rare Disease Network, Dr David Brown, the inventor of Viagra and ex-Global Head of Drug Discovery at Roche and Dr Andreas Bender, a lecturer and researcher at Cambridge University’s Centre for Molecular Sciences Informatics, Healx is a technology company developing treatments for rare diseases by using Artificial Intelligence (AI), deep pharmacological expertise and extensive patient engagement. Its approach combines technology with a large collection of insights from rare disease patient groups.
At the core ot the company’s efforts there is HealNet, a comprehensive knowledge base for rare disease, mapping over one billion unique disease, patient and drug interactions. HealNet was built and is maintained using a variety of machine learning methods applied to a wide range of data types from both publicly available and exclusive sources including scientific literature, patents, clinical trials, disease symptoms, drug targets, multi-omic data and underlying chemical structures.